VCA Stocks

Revance Therapeutics, Inc. today announced the completion of an additional $8 million investment to the Series C financing that was completed in December 2007.  “We believe the application of botulinum toxin type A without an injection using Revance’s MTS technology, as well as the development of new botulinum toxin molecules, will be of interest globally and play a major role in the development of new non-invasive treatment alternatives.”  Revance is a privately held specialty biopharmaceutical company focused on developing innovative products in the aesthetic medicine category. Revance has developed a platform technology allowing non-invasive transcutaneous delivery of botulinum toxin molecules and other potent macromolecules across skin and barrier membranes. This novel technology enables local, targeted drug delivery without patches, needles or other invasive procedures. Revance has exclusive worldwide rights to novel botulinum toxin type A proteins for use worldwide across topical and injectable dose forms and all cosmetic and therapeutic indications. Revance has clinical-stage programs in facial aesthetics and hyperhidrosis, and preclinical programs in hyperpigmentation and acne, and our over-the-counter skin care brand RELASTIN.